The FOXO4-DRI benefits you will see listed are not invented. Each traces to a real, published experiment. What gets dropped in the retelling is the organism, and that omission does most of the misleading. A result in an aged mouse and a result in a person are different claims, and for this compound every single result belongs to the first category.
Key takeaways
- Every published FOXO4-DRI result comes from mice, rats or cultured cells. There is no human trial evidence of any kind.
- The 2017 study reported restored fitness, fur density and renal function in aged mice, plus protection against chemotherapy toxicity.
- For a body-composition reader the relevant argument is senescent-cell accumulation in ageing muscle, which is about repair capacity rather than growth.
- FOXO4-DRI is not anabolic. It does not act on myostatin, activin or follistatin, and no study in any species has measured hypertrophy or strength.
- Senolysis is not uniformly beneficial. Clearing senescent cells has documented harms in at least one disease model.
The vendor we point lifters to
FOXO4-DRI from Ascension Peptides
Independently assayed material, dispatched from the US. The vial drops by half with the code below.
One vial size only, so there is no bulk-tier price break to chase on a single order. Per-mg is quoted at the labelled 10 mg: the two published batch reports measured 11.41 mg and 8.30 mg, so the real figure moves with the batch. Buying 3, 5 or 10 takes 3%, 5% or 10% off. Free shipping starts at $250. The vendor spells the product FOX04 with a zero, including in the link above.
- Batch-specific third-party lab report
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. FOXO4-DRI is not an approved medicine anywhere and has never been tested in a human trial. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified September 2, 2026.
FOXO4-DRI benefits, graded against the evidence
Read the organism column first. It is the one that determines how much weight any row can carry.
| Claimed benefit | What was actually shown | Organism | Strength |
|---|---|---|---|
| Clears senescent cells | Selective apoptosis via FOXO4 and p53 disruption | Mouse and cultured cells | Well replicated |
| Restores physical fitness | Improved running wheel performance in aged animals | Mouse | Single foundational study |
| Restores fur density | Regrowth in fast-ageing and naturally aged animals | Mouse | Single foundational study |
| Improves kidney function | Reduced markers of renal dysfunction | Mouse | Single foundational study |
| Protects against chemotherapy toxicity | Neutralised doxorubicin-induced damage | Mouse | Foundational, model-specific |
| Raises testosterone | Targeted senescent Leydig cells in aged animals | Mouse | One study, 2020 |
| Improves sperm production | Reduced inflammatory secretion from senescent cells | Mouse | One study, 2024 |
| Rejuvenates cartilage cells | Removed senescent cells from expanded chondrocytes | Human cells in culture | In vitro only |
| Reduces fibrosis | Improved bleomycin-induced pulmonary fibrosis | Mouse | One study, 2022 |
| Builds or preserves muscle | Nothing. No study has measured it | None | No evidence |
| Extends human lifespan | Nothing. No human study exists | None | No evidence |
The last two rows are the ones worth dwelling on, because they are the reasons most people arrive at this page.
What the foundational study actually found
Baar and colleagues, Cell, 2017 is where nearly every claim originates. The work identified FOXO4 as the protein keeping senescent cells alive, by binding p53 and preventing it from triggering apoptosis. The designed peptide disrupts that interaction, p53 is excluded from the nucleus, and the senescent cell dies. Healthy cells are largely spared, which is the selectivity that makes the approach interesting.
In living animals the group showed three things. In mice given doxorubicin, the peptide reduced the chemotherapy's toxicity. In XpdTTD/TTD mice, a strain that ages rapidly due to a DNA-repair defect, and in naturally aged mice, it restored fitness, fur density and renal function.
Those are real findings and they were striking enough to make the paper widely covered. They are also, nine years later, still mouse findings. The mechanism has been elaborated since, notably by a 2025 Nature Communications paper identifying the disordered p53 transactivation domain as the binding target. Mechanistic depth is not the same as clinical evidence, and no trial has followed.
The muscle argument, stated carefully
This is a site about myostatin, follistatin and lean-mass retention, so the reason a senolytic appears here needs to be exact rather than gestural.
Senescent cells accumulate in ageing tissue, including skeletal muscle. They stop dividing but remain metabolically active, secreting an inflammatory mixture of cytokines and proteases known as the senescence-associated secretory phenotype. That secretory background is implicated in why satellite cells, the resident stem-cell population responsible for muscle repair, respond less effectively to damage in older animals. Sarcopenia is not solely a story of anabolic signalling declining; the repair environment degrades too.
A compound that removes senescent cells is therefore addressing one contributor to that environment. That is a coherent hypothesis and it is the honest version of the muscle case.
What it is not is a growth mechanism. FOXO4-DRI does not interact with myostatin, activin or follistatin signalling. It does not stimulate protein synthesis. No study in any species has used hypertrophy, strength or lean mass as an outcome measure. If you are looking for compounds with an anabolic rationale, the muscle-growth peptide material covers that ground and this compound is not on it, while the follistatin work is the closer analogue for growth-pathway interest.
The distinction is worth holding because the marketing around senolytics frequently blurs it. Maintenance of tissue quality and promotion of tissue growth are different claims with different evidence behind them, and only the first has even a preclinical case here.
Where the benefits case has a genuine counterweight
A benefits article that only lists benefits is not describing the literature.
Senescent cells are not simply damaged cells awaiting disposal. Senescence is, among other things, a tumour-suppressive mechanism: it is how a cell that has accumulated dangerous mutations is taken out of the replicative pool. Senescent cells also participate in wound healing and tissue remodelling. Removing them removes those functions too.
That is not hypothetical. A 2023 paper in Circulation reported that eliminating senescent cells could promote the development and progression of pulmonary hypertension. Whatever the net effect of senolysis turns out to be, it is not uniformly positive, and it plainly depends on tissue and context.
Combine that with the absence of any human safety data and the honest summary is that FOXO4-DRI has an interesting preclinical profile and an entirely unknown human one.
Frequently asked questions
What are the proven benefits of FOXO4-DRI?
None are proven in humans, because no human trial has been conducted. In mice the 2017 study reported restored fitness, fur density and renal function in aged animals, and protection against doxorubicin toxicity. Those results have not been reproduced in people.
Does FOXO4-DRI build muscle?
No. It has no anabolic mechanism, does not act on the myostatin pathway, and no study in any organism has measured muscle size, strength or performance. The connection to muscle is indirect and concerns senescent-cell accumulation as one factor in age-related decline in repair capacity.
Has FOXO4-DRI been tested in humans at all?
Not in a registered trial. One 2021 study applied it to human chondrocytes expanded in culture, which is human tissue in a dish rather than a person. ClinicalTrials.gov lists no interventional study of this peptide in humans.
Are there downsides to clearing senescent cells?
Yes, and they are documented. Senescence suppresses tumour formation and contributes to wound healing, so removing those cells removes useful functions alongside harmful ones. A 2023 Circulation paper found senescent-cell elimination could worsen pulmonary hypertension.